Top 4 Biosimilar Developments of 2021

December 10, 2021

2021 was an outstanding year for biosimilar medications, as they increased market share and adoption by healthcare providers and the first biosimilar and interchangeable insulin was approved by the FDA. Take a look at Managed Healthcare Executive's top four biosimilar developments of 2021.

Priming the Pump for Interchangeable Biosimilars By Preferencing Semglee

November 04, 2021

By giving Semglee, the interchangeable biosimilar for Lantus, a preferred spot on its formulary, the Prime Therapeutics says it is setting the stage for other interchangeables coming down the pike, including the one for Humira.

Biosimilar Growth Impressive But New Policies Needed, AAM Exec Says

October 08, 2021

Three pieces of legislation that would provide incentives to prescribers and put generics and biosimilars in favorable formulary tiers would speed further prescribing and use of biosimilars, Christine Simmon told Managed Healthcare Executive.®

AAO Spokesperson: FDA Approval of Byooviz, First Biosimilar to Lucentis, Is “Significant"

October 07, 2021

Exactly how Byooviz will be priced is unclear, noted George W. Williams, M.D., a retina specialist and past president of the American Academy of Ophthalmology. The exact cost savings will help determine whether the biosimilar gains acceptance.